Overview

Antipsychotics and Risk of Hyperglycemic Emergencies

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR)
Drug Safety and Effectiveness Network, Canada
Treatments:
Antipsychotic Agents
Aripiprazole
Chlormezanone
Chlorpromazine
Chlorprothixene
Clopenthixol
Clozapine
Flupenthixol
Flupenthixol decanoate
Fluphenazine
Fluphenazine depot
Fluphenazine enanthate
Fluspirilene
Haloperidol
Haloperidol decanoate
Loxapine
Mesoridazine
Methotrimeprazine
Olanzapine
Paliperidone Palmitate
Perphenazine
Pimozide
Quetiapine Fumarate
Risperidone
Tetrabenazine
Thioridazine
Thiothixene
Trifluoperazine
Ziprasidone
Criteria
Inclusion Criteria:

- Patients with a with a first-time prescription for an antipsychotic medication

- Patients at least 18 years of age at cohort entry (except Alberta, Ontario, and Nova
Scotia, where patients will be a least 66 years of age)

- Patients with at least 1 year of history in the database

Exclusion Criteria:

- Patients aged <18 years on the date of cohort entry (or < 66 years in Alberta, Ontario
and Nova Scotia)

- Received a prescription for an antipsychotic medication in the 365 days prior to
cohort entry

- Patients who were hospitalized with the primary study outcome <30 days prior to cohort
entry

- Had <1 year of provincial Medicare or GPRD enrollment preceding cohort entry

- Hospitalized for >30 consecutive days in the 365 days prior to cohort entry

- Received renal dialysis or palliative care in the 365 days prior to cohort entry

- Patients in a long term care facility

- Patients who received >1 antipsychotic medication on the date of cohort entry